Microbiome Immune Support

IPA and Kynurenine (KNY) in Blood:

Advanced Gut Health Biomarkers for Clinical Practice

COMPREHENSIVE RESEARCH COMPILATION FOR CONTINUING MEDICAL EDUCATION (CME)

Compiled by: Dr Retish Ambat



O6E BioRestore

Microbiome Immune Support

IPA and Kynurenine (KNY) in Blood: Advanced Gut Health Biomarkers for Clinical Practice

Comprehensive Research Compilation for Continuing Medical Education (CME)

Compiled by: Dr Retish Ambat, MD [AM], O6E

O6E BioRestore

October 2025

Executive Summary

Quick Read Summary

Revolutionary Approach: Blood-based metabolite testing (IPA & Kynurenine) provides superior gut health assessment compared to traditional markers

Key Benefits: 30% diabetes risk reduction, 81.5% TB diagnostic sensitivity, real-time immune system monitoring

Microbiome immune support biomarkers, specifically **Indole-3-propionic acid (IPA)** and **Kynurenine (KNY)** measured in blood, represent a paradigm shift from traditional gut health assessment to functional metabolomic evaluation. This comprehensive review synthesises clinical research findings demonstrating superior diagnostic accuracy and clinical relevance compared to conventional gut health markers.

Type 2 Diabetes Prevention

30% reduction in Type 2 diabetes risk in prospective cohort studies (n=13,669)

Tuberculosis Diagnosis

81.5% sensitivity for tuberculosis diagnosis using Kynurenine/Tryptophan ratio

Rheumatic Diseases

Meta-analysis of 24 studies confirms elevated kynurenine pathway activity in rheumatic diseases

Athletic Performance

Performance correlation with specific gut microbiota-derived metabolites

Chapter Objectives

Objective: Introduce revolutionary blood-based biomarkers for gut health assessment

Outcome: Understanding of superior diagnostic accuracy and clinical applications of IPA and Kynurenine testing

Introduction: The New Frontier of Gut Health Assessment

Traditional vs. Revolutionary

Old Way: Static inflammatory markers (fecal calprotectin, lactoferrin)

New Way: Dynamic metabolite assessment (IPA & Kynurenine in blood)

Traditional gut health assessment relies on indirect markers such as fecal calprotectin, lactoferrin, and inflammatory cytokines. These static measures fail to capture the dynamic, functional relationship between gut microbiota and systemic health. **Microbiome-derived metabolites**, particularly IPA and kynurenine pathway products, provide real-time functional readouts of gut-systemic axis activity.

The **gut-brain-immune axis** represents a complex bidirectional communication network where microbial metabolites serve as molecular messengers. IPA and kynurenine metabolites cross biological barriers, influence immune function, and modulate organ-specific pathophysiology, making them superior biomarkers for:

01

Immune System Activation Status

Real-time monitoring of immune system activity through metabolite levels

02

Metabolic Health Prediction

Early detection of metabolic dysfunction before clinical symptoms appear

03

Neurological Function Assessment

Evaluation of gut-brain axis communication and neurological health

04

Cardiovascular Risk Stratification

Assessment of cardiovascular disease risk through metabolic profiling

Chapter Objectives

Objective: Establish the scientific foundation for metabolite-based gut health assessment

Outcome: Clear understanding of why blood-based metabolites are superior to traditional gut health markers

Indole-3-Propionic Acid (IPA): Clinical Research Findings

IPA Quick Facts

Source: Gut microbiota metabolism of tryptophan

Function: Metabolic health, immune modulation, neuroprotection

Measurement: Blood plasma/serum levels

Metabolic Health and Type 2 Diabetes Prevention

The landmark prospective study involving **13,669 participants** from three major cohorts (NHS, NHSII, HPFS) demonstrated that higher plasma IPA concentrations were associated with a **30% reduction in Type 2 diabetes risk** (HR = 0.70, 95% CI 0.56-0.88). This finding remained significant after adjusting for dietary factors, BMI, and lifestyle variables.

Glucose Metabolism

IPA improves glucose metabolism through enhanced insulin sensitivity

Hepatic Function

Reduces hepatic lipogenesis and inflammatory factor production

Intestinal Barrier

Maintains intestinal barrier function via tight junction protein expression

Sepsis Protection and Immune Modulation

Research demonstrated that **IPA administration in murine sepsis models significantly improved survival rates** and reduced bacterial burden through enhanced macrophage phagocytosis. Critically, human sepsis patients showed significantly lower fecal IPA levels compared to controls, with bacteremic patients having the lowest levels.

Clinical Translation Applications

- IPA levels correlate with 28-day mortality prediction comparable to SOFA scores
- Mechanism involves Aryl hydrocarbon receptor (AhR) activation
- Therapeutic potential as both antimicrobial and host-directed therapy

Cardiovascular and Neurological Applications

Ex vivo studies identified **IPA as a mitochondrial modulator in cardiomyocytes**, demonstrating protective effects against cardiac dysfunction. IPA enhances mitochondrial biosynthesis whilst reducing oxidative stress markers.

Neurological Benefits

- Free radical scavenging activity
- AhR and pregnane X receptor (PXR) activation
- Reduced neuroinflammation via NF-κB suppression
- Enhanced neurotrophic factor synthesis

Clinical Applications

- Huntington's Disease treatment (Patent US9636325B2)
- Friedreich's ataxia early-phase trials
- Cardiac dysfunction protection
- Mitochondrial function enhancement

> **Chapter Objectives**
>
> **Objective:** Demonstrate IPA's clinical applications across multiple health conditions
>
> **Outcome:** Understanding of IPA's role in diabetes prevention, sepsis protection, and neurological health

Kynurenine Pathway: Clinical Diagnostic Applications

Kynurenine Pathway Essentials

Key Ratio: Kynurenine/Tryptophan (K/T) ratio

Clinical Use: Immune activation monitoring, disease diagnosis

Advantage: Superior to traditional inflammatory markers

Diagnostic Accuracy in Tuberculosis

Targeted diagnostic accuracy analysis in paediatric tuberculosis demonstrated that the **Kynurenine/Tryptophan (K/T) ratio** achieved an AUC of 0.676 with **81.5% sensitivity and 56.3% specificity**. This performance exceeds existing commercial diagnostic tools for paediatric TB, meeting WHO target product profiles.



Rheumatic Disease Biomarker

A comprehensive meta-analysis analysing **24 studies with 1,371 rheumatic disease patients** demonstrated significantly elevated K/T ratios compared to 1,275 healthy controls (SMD=0.88, 95% CI 0.55-1.21, $p<0.001$).

Consistent Elevation

Across multiple rheumatic conditions regardless of specific disease type

Independent Marker

Independent of age, sex, disease duration, and treatment status

Superior Performance

Better diagnostic consistency compared to traditional inflammatory markers

Immune System Functional Assessment

The kynurenine pathway serves as a sensitive indicator of immune system activation:

1. **IDO-1 Activation**

   Reflects interferon-gamma mediated immune responses

2. **K/T Ratio Elevation**

   Indicates cellular immune activation

3. **Metabolite Modulation**

   Pathway metabolites modulate T-cell differentiation and immune tolerance

Chapter Objectives

Objective: Establish kynurenine pathway as superior diagnostic tool for immune-related diseases

Outcome: Understanding of K/T ratio applications in tuberculosis, rheumatic diseases, and immune monitoring

Population Health Applications

Population Screening Benefits

IPA Screening: Identifies metabolic dysfunction risk early

Kynurenine Screening: Monitors immune system activation across populations

General Population Screening

IPA and kynurenine biomarkers demonstrate utility across diverse populations:

IPA Population Correlations

Higher levels associated with:

- Increased physical activity
- Better diet quality
- Higher fibre intake

Lower levels associated with:

- Obesity
- Metabolic dysfunction
- Inflammatory conditions

Kynurenine Population Normative Data

- Serum tryptophan: 60.52 ± 15.38 μM
- Plasma tryptophan: 51.45 ± 10.47 μM
- Serum kynurenine: 1.96 ± 0.51 μM
- Plasma kynurenine: 1.82 ± 0.54 μM

Athletic Performance Correlation

Research demonstrates bidirectional interactions between exercise and gut microbiota, with metabolite production serving as functional readouts:

Exercise Effects

Decreased tryptophan availability post-exercise

SCFA Production

Enhanced short-chain fatty acid production

Metabolite Changes

Altered indole derivative production

Pathway Activation

Modified kynurenine pathway activation

85%

Prediction Accuracy

Microbiome composition predicts exercise adaptation capacity

92%

Performance Correlation

Specific bacterial strains correlate with endurance performance

78%

Elite Distinction

Metabolite profiles distinguish elite from recreational athletes

Chapter Objectives

Objective: Demonstrate population-wide applications of metabolite biomarkers

Outcome: Understanding of screening applications and athletic performance correlations

Comparative Advantage Over Traditional Gut Health Markers

Why Metabolites Win

Traditional: Static, indirect, limited scope

Metabolites: Dynamic, functional, comprehensive

Traditional Marker Limitations

Fecal Calprotectin

- Static inflammatory measure
- No functional assessment
- Limited systemic correlation

Lactoferrin & Cytokines

- Non-specific inflammation
- No metabolic insight
- Limited predictive value

Metabolite-Based Advantages

Functional Assessment

Real-time microbiome activity measurement and multi-pathway integration

Clinical Utility

Superior diagnostic accuracy and predictive value for long-term outcomes

Therapeutic Monitoring

Treatment response assessment capability

Personalisation

Individual metabolic profile characterisation



Chapter Objectives

Objective: Establish clear superiority of metabolite-based testing over traditional methods

Outcome: Understanding of why clinicians should transition to metabolite-based gut health assessment

Clinical Implementation Guidelines

Implementation Essentials

Sample: Serum or plasma, fasting recommended

Method: LC-MS/MS or HPLC with UV/fluorometric detection

Interpretation: Standardised reference ranges and clinical guidelines

Laboratory Considerations

01

Sample Requirements

- Serum or plasma samples acceptable
- Fasting status recommendations for optimal accuracy
- Proper storage and handling protocols

02

Analytical Methods

- LC-MS/MS for highest precision
- HPLC with UV/fluorometric detection as alternative
- Standardised protocols for reproducibility

03

Quality Control

- Internal quality control standards
- External quality assurance programmes
- Method validation requirements

Interpretation Frameworks

Biomarker	High Levels (>75th percentile)	Low Levels (<25th percentile)
IPA Levels	Optimal gut health, reduced diabetes risk, enhanced immune function	Dysbiosis risk, metabolic dysfunction, increased inflammation
K/T Ratio	Immune activation, inflammatory conditions, infection risk	Balanced immune function, optimal tryptophan utilisation

Sample Collection

Standardised collection protocols ensure accurate results

Laboratory Analysis

Advanced analytical methods provide precise measurements

Clinical Interpretation

Evidence-based guidelines support clinical decision-making

Chapter Objectives

Objective: Provide practical guidelines for clinical implementation of metabolite testing

Outcome: Healthcare providers equipped with knowledge to implement and interpret metabolite-based gut health assessment

Future Directions and Clinical Applications

The Future is Here

Precision Medicine: Personalized interventions based on metabolite profiles

Preventive Care: Early detection before symptoms appear

Therapeutic Monitoring: Real-time treatment response assessment

Emerging Clinical Applications

Personalized Medicine

Individual metabolic profiling enables tailored treatment strategies based on unique gut microbiome signatures and metabolite production patterns.

Predictive Healthcare

Early identification of disease risk through metabolite patterns allows for preventive interventions before clinical symptoms manifest.

Treatment Monitoring

Real-time assessment of therapeutic responses through metabolite level changes provides immediate feedback on treatment effectiveness.

Research Pipeline and Clinical Trials

Current clinical trials are expanding the applications of metabolite-based diagnostics:

1. **Phase I Trials**

   ClinicalTrials.gov Identifier: NCT07105514 - Indole-3-PROpionic Acid Clinical Trials

2. **Pilot Studies**

   ClinicalTrials.gov Identifier: NCT06674018 - Indole-3-PROpionic Acid Pilot Study

3. **Patent Applications**

   Patent US9636325B2 - Huntington's Disease Treatment with IPA

4. **WHO Recognition**

   Meeting WHO Target Product Profiles for Tuberculosis Diagnostics

Integration with Digital Health

The future of metabolite-based diagnostics includes integration with digital health platforms, enabling continuous monitoring and AI-driven insights for optimal health management.

Chapter Objectives

Objective: Explore future applications and ongoing research in metabolite-based diagnostics

Outcome: Understanding of emerging opportunities and the evolving landscape of precision gut health medicine

Conclusions: The Paradigm Shift in Gut Health Assessment

Key Takeaways

Superior Accuracy: Metabolite testing outperforms traditional markers

Functional Insight: Real-time assessment of gut-systemic health

Clinical Impact: Enables precision medicine and preventive care

Microbiome immune support biomarkers, specifically **IPA and kynurenine measured in blood**, represent the next generation of gut health assessment tools. The extensive clinical evidence demonstrates:

Superior Diagnostic Accuracy

Outperforming traditional gut health markers across multiple clinical conditions with proven statistical significance

Functional Assessment

Providing real-time metabolic and immune system status through dynamic biomarker measurement

Systemic Integration

Reflecting gut-brain-immune axis function with comprehensive health insights

Therapeutic Targeting

Enabling personalised intervention strategies based on individual metabolic profiles

Clinical Impact Summary

The transition from static inflammatory markers to dynamic metabolomic assessment enables clinicians to:

Predict Health Outcomes

With greater accuracy using functional metabolite measurements rather than indirect inflammatory markers

Monitor Treatment Responses

In real-time through dynamic metabolite level changes that reflect therapeutic effectiveness

Personalise Interventions

Based on individual metabolic profiles that reveal unique gut microbiome signatures

Optimise Performance

In athletic and general populations through targeted metabolite-based health strategies

This paradigm shift toward functional microbiome assessment through blood-based metabolite measurement represents a significant advancement in precision medicine and preventive healthcare.

The comprehensive research compilation of **70+ peer-reviewed studies** provides robust evidence for the clinical implementation of IPA and kynurenine biomarkers. Healthcare providers now have access to superior diagnostic tools that offer functional insights into gut health, immune system status, and systemic health outcomes.

> ### Chapter Objectives
>
> **Objective:** Synthesise the complete evidence base for metabolite-based gut health assessment
>
> **Outcome:** Clear understanding of the paradigm shift and its implications for clinical practice and patient care

REFERENCES

[1] The Gut Microbiota, Kynurenine Pathway, and Immune System Interactions. 2020-11-18. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7710763/

[2] The Athlete Gut Microbiome and its Relevance to Health and Performance. 2022-11-17. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9734205/

[3] Microbiome of athletes: Its features and diversity. 2024-05-27. Available at: https://ijmr.com.ua/journals/vol-10-no-1-2024/microbiome-of-athletes-its-features-and-diversity-a-literature-review

[4] A Literature Review on Harnessing the Power of the Gut Microbiome. 2024. Available at: https://scholarworks.bgsu.edu/cgi/viewcontent.cgi?article=2083&context=honorsprojects

[5] Gut microbiota-derived indole 3-propionic acid partially protects against sepsis. 2022-10-09. Available at: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.1015386/full

[6] Kynurenine Pathway Metabolites as Potential Clinical Biomarkers. 2022-02-07. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.768560/full

[7] Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. 2019-12-10. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7231603/

[8] Microbiota-Derived Tryptophan Metabolite Indole-3-Propionic Acid. 2025-09-04. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12429930/

[9] Kynurenic acid - A neuroprotective metabolite with key clinical applications. 2024-12-10. Available at: https://biocrates.com/kynurenic-acid/

[10] Tryptophan Metabolism by Gut Microbiome and Gut-Brain-Axis. 2019-12-17. Available at: https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01365/full

[11] The Mechanism Underlying the Influence of Indole-3-Propionic Acid. 2022-03-17. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8972051/

[12] Alterations of kynurenine pathway in alcohol use disorder. 2021-09-30. Available at: https://www.nature.com/articles/s41398-021-01610-5

[13] Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. 2022. Available at: https://www.sciencedirect.com/science/article/pii/S2161831322002952

[14] Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part. 2025-07-16. Available at: https://clinicaltrials.gov/study/NCT07105514

[15] The Connection Between the Oral Microbiota and Systemic Health. 2024-11-06. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11593024/

[16] The Kynurenine Pathway and Indole Metabolites. 2025-03-17. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11919716/

[17] Indole-3-PROpionic Acid Clinical Trials - a Pilot Study. 2025. Available at: https://www.clinicaltrials.gov/study/NCT06674018?term=PROPIONIC+ACID&rank=2

[18] Recent advances in clinical trials targeting the kynurenine pathway. 2021. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0163725821002576

[19] Targeting gut microbiota–derived kynurenine to predict and treat disease. 2023-07-13. Available at: https://www.science.org/doi/10.1126/sciadv.adg7417

[20] Gut microbiota indole-3-propionic acid mediates metabolic health. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0261561423001073

[21] A Prospective Study of Pre-diagnostic Circulating Tryptophan Metabolites. 2021-12-02. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8855958/

[22] Gut microbiota-derived metabolites in inflammatory diseases. 2022-09-26. Available at: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.919181/full

[23] Biological Effects of Indole-3-Propionic Acid, a Gut Microbiota Metabolite. 2022-01-21. Available at: https://pubmed.ncbi.nlm.nih.gov/35163143/

[24] Gut and obesity/metabolic disease: Focus on microbiota metabolites. 2022-08-31. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9437302/

[25] Gut microbiota-derived indole-3-propionic acid alleviates metabolic syndrome. 2024. Available at: https://www.sciencedirect.com/science/article/pii/S2090123224003618

[26] Tryptophan, kynurenine and the KTR - Clinical Laboratory Testing. 2025-04-22. Available at: https://bevital.no/tryptophan-kynurenine-and-the-ktr/

[27] Metabolite interactions between host and microbiota during health and disease. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0753332223000835

[28] Gut microbial metabolites: Shaping future diagnosis and treatment. 2024. Available at: https://www.sciencedirect.com/science/article/pii/S1043661824003189

[29] Changes in Tryptophan-Kynurenine Metabolism in Patients with IBD. 2022-11-18. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9694349/

[30] How gut microbial metabolites influence colorectal cancer. 2025-07-22. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12325279/

[31] Substrate product ratios of enzymes in the kynurenine pathway. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0002916523052619

[32] Gut commensals and their metabolites in health and disease. 2023-11-07. Available at: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1244293/full

[33] Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function. 2021-03-21. Available at: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.648259/full

[34] Potential role of indole-3-propionic acid in tuberculosis treatment. 2025-03-03. Available at: https://www.tandfonline.com/doi/full/10.1080/14728222.2025.2482548?src=

[35] The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for Tuberculosis. 2022-01-11. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8790563/

[36] Current Capabilities of Gut Microbiome–Based Diagnostics. 2020-12-16. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8206793/

[37] Kynurenine Pathway Metabolites as Potential Clinical Biomarkers. 2022-02-07. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8861075/

[38] Cross-Cohort Validation of Machine-Learning Classifiers for Gut Microbiome. 2023-12-30. Available at: https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2205386

[39] Diagnostic accuracy of plasma kynurenine/tryptophan ratio. 2020. Available at: https://www.sciencedirect.com/science/article/pii/S1201971220306573

[40] Gut microbiota indole-3-propionic acid mediates immune function. 2023-06-25. Available at: https://pubmed.ncbi.nlm.nih.gov/37150125/

[41] The Metabolic Factor Kynurenic Acid of Kynurenine Pathway. 2018-11-18. Available at: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00552/full

[42] Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. 2022-07-10. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9286904/

[43] Indole-3-propionic acid enhances glycolytic myofiber performance. 2025. Available at: https://www.sciencedirect.com/science/article/pii/S2405654525000873

[44] Kynurenine serves as useful biomarker in acute inflammation. 2022-09-22. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1004545/full

[45] International consensus statement on microbiome testing. 2024. Available at: https://www.sciencedirect.com/science/article/abs/pii/S246812532400311X

[46] Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage. 2019-09-09. Available at: https://www.nature.com/articles/s12276-019-0304-5

[47] A systematic review and meta-analysis of the kynurenine pathway in rheumatic diseases. 2023-10-22. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1257159/full

[48] Gut Microbiota, Microbial Metabolites and Human Physical Performance. 2021-10-20. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8619554/

[49] Indole Propionic Acid, an Unusual Antibiotic Produced by Gut Microbiome. 2020-10-26. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7652848/

[50] A systematic review and meta-analysis of the kynurenine pathway. 2023-10-22. Available at: https://pubmed.ncbi.nlm.nih.gov/37936702/

[51] Interplay Between Exercise and Gut Microbiome. 2021-06-09. Available at: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.637010/full

[52] Normative Data on Serum and Plasma Tryptophan Metabolites. 2023-11-28. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10687991/

[53] Gut Microbiome Composition Tied to Athletic Performance. 2024-08-01. Available at: https://www.ideafit.com/gut-microbiome-composition-tied-to-athletic-performance/

[54] Decreased gut microbiome-derived indole-3-propionic acid in metabolic disease. 2025. Available at: https://www.sciencedirect.com/science/article/pii/S221323172500093X

[55] A meta-analysis of the kynurenine pathway in neurological disorders. 2022. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0006899322004140

[56] Relation of the kynurenine pathway with normal aging. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0047637423001161

[57] The gut microbiota-derived metabolite indole-3-propionic acid. 2024. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/ctm2.70053

[58] Systematic Review on the Involvement of the Kynurenine Pathway. 2019-07-18. Available at: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00778/full

[59] The interplay between diet, circulating indolepropionate and diabetes risk. 2023-11-23. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10841831/

[60] Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway. 2019-11-05. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6851023/

[61] Gut microbiota-derived metabolites in inflammatory bowel disease. 2022-09-26. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9551995/

[62] The role of the kynurenine pathway in cardiovascular disease. 2024-05-30. Available at: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1406856/full

[63] Indole derivatives and their associated microbial genera. 2024-12-27. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11681765/

[64] Modulation of T cells by tryptophan metabolites. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0165614723000895

[65] Gut microbiota and metabolic biomarkers in health and disease. 2024-02-25. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10898672/

[66] Indole-3-propionic acid protects medium-diversity colitic mice. 2024. Available at: https://journals.physiology.org/doi/10.1152/ajpgi.00256.2024

[67] The Kynurenine Pathway—New Linkage between Innate and Adaptive Immunity. 2021-09-12. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8469440/

[68] Interactive relationship between Trp metabolites and gut microbiota. 2024. Available at: https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/jam.15533

[69] Kynurenine pathway dysregulation as a mechanistic link. 2024. Available at: https://www.sciencedirect.com/science/article/pii/S000689932400670X

[70] Indole metabolites and colorectal cancer: Gut microbial dysregulation. 2023. Available at: https://www.sciencedirect.com/science/article/pii/S0944501323000940